Comparison of Pain Intensity after Pan Retinal Photocoagulation Performed with Yellow versus Green Laser in Patients with Proliferative Diabetic Retinopathy

Muhammad Usman Ghani; Muhammad Ahsan Mukhtar; Taimoor Ashraf Khan; Teyyeb Azeem Janjua; Umar Ijaz; Waseem Yousaf

doi:10.51253/pafmj.v76iSUPPL-1.8958

Authors

Muhammad Usman Ghani Department of Ophthalmology, Armed Forces Institute of Ophthalmology, Rawalpindi/National University of Medical Sciences (NUMS) Pakistan
Muhammad Ahsan Mukhtar Department of Ophthalmology, Armed Forces Institute of Ophthalmology, Rawalpindi/National University of Medical Sciences (NUMS) Pakistan
Taimoor Ashraf Khan Department of Ophthalmology, Armed Forces Institute of Ophthalmology, Rawalpindi/National University of Medical Sciences (NUMS) Pakistan
Teyyeb Azeem Janjua Department of Ophthalmology, Armed Forces Institute of Ophthalmology, Rawalpindi/National University of Medical Sciences (NUMS) Pakistan
Umar Ijaz Department of Ophthalmology, Wah Medical College, Wah Cantt Rawalpindi Pakistan
Waseem Yousaf Department of Ophthalmology, Armed Forces Institute of Ophthalmology, Rawalpindi/National University of Medical Sciences (NUMS) Pakistan

DOI:

https://doi.org/10.51253/pafmj.v76iSUPPL-1.8958

Keywords:

Diabetic Retinopathy, Proliferative Diabetic Retinopathy, Green Laser, Yellow Laser, Pan Retinal Photocoagulation.

Abstract

Objective: To compare the patient’s perceived pain during yellow versus green laser Pan Retinal Photocoagulation (PRP) using standardized 10 points on Visual Analogue Scale.

Study Design: Prospective, single center, Quasi-experimental study.

Place and Duration of Study: Armed Forces Institute of Ophthalmology Rawalpindi, Pakistan from Aug 2021 to Jan 2022.

Methodology: Study included a total of 56 eyes of 56 individuals diagnosed as cases of Proliferative Diabetic Retinopathy, referred by a consultant ophthalmologist for Pan Retinal Photocoagulation (PRP). Patients were assigned to one of the two groups for choice of laser (Group-A received yellow and Group-B received conventional green laser).

Results: Lasers were applied to right eyes of 26(46.4%) patients while left eye of 30 patients (53.6%). Twenty-seven (48.2%) of them underwent conventional green laser while 29(51.8%) underwent yellow laser panretinal photocoagulation. Mean of total number of laser burns applied was 1582.7±359.6, ranging from 730 to 2100 burns. Duration of session ranged from 2 minutes to 29 minutes, with mean duration of 18.7±4.5 minutes. Overall, mean score of patient’s perceived pain remained 4.04±1.57 (out of 10 on Visual Analogue Scale).

Conclusion: The patient-perceived pain was significantly less by the use of yellow retinal laser for PRP as compared to green laser. The number of burns required for PRP was more by using yellow laser. However, no significant difference was noted in duration of lasers with both lasers.

Downloads

Download data is not yet available.

References

1. Stewart MW. Treatment of diabetic retinopathy: Recent advances and unresolved challenges. World J Diabetes 2016; 7(16): 333-341. https://doi.org/10.4239/wjd.v7.i16.333

2. Mason JO, Yunker JJ, Vail R, McGwin G. Intravitreal bevacizumab (Avastin) prevention of panretinal photocoagulation-induced complications in patients with severe proliferative diabetic retinopathy. Retina 2008; 28(9): 1319-1324.

https://doi.org/10.1097/IAE.0b013e31818356fb

3. Sun JK, Glassman AR, Beaulieu WT. Rationale and Application of the Protocol S Anti-Vascular Endothelial Growth Factor Algorithm for Proliferative Diabetic Retinopathy. Ophthalmology 2019; 126(1): 87-95.

https://doi.org/10.1016/j.ophtha.2018.08.001

4. Sivaprasad S, Prevost AT, Vasconcelos JC. Clinical efficacy of intravitreal aflibercept versus panretinal photocoagulation for best corrected visual acuity in patients with proliferative diabetic retinopathy at 52 weeks (CLARITY): a multicentre, single-blinded, randomised, controlled, phase 2b, non-inferiority trial. Lancet 2017; 389(10085): 2193-2203.

https://doi.org/10.1016/S0140-6736(17)31193-5

5. Shakarchi FI, Shakarchi AF, Al-Bayati SA. Timing of neovascular regression in eyes with high-risk proliferative diabetic retinopathy without macular edema treated initially with intravitreous bevacizumab. Clin Ophthalmol 2018; 13(1): 27-31.

https://doi.org/10.2147/OPTH.S182420

6. Yates WB, Mammo Z, Simunovic MP. Intravitreal anti-vascular endothelial growth factor versus panretinal LASER photocoagulation for proliferative diabetic retinopathy: a systematic review and meta-analysis. Can J Ophthalmol 2021; 56(6): 355-363. https://doi.org/10.1016/j.jcjo.2021.01.017

7. Sugimoto M, Ichio A, Mochida D. Multiple Effects of Intravitreal Aflibercept on Microvascular Regression in Eyes with Diabetic Macular Edema. Ophthalmol Retina 2019; 3(12): 1067-1075.

https://doi.org/10.1016/j.oret.2019.06.005

8. Bressler SB, Almukhtar T, Aiello LP. Diabetic Retinopathy Clinical Research Network. Green or yellow laser treatment for diabetic macular edema: exploratory assessment within the Diabetic Retinopathy Clinical Research Network. Retina 2013; 33(10): 2080-2088.

https://doi.org/10.1097/IAE.0b013e318295f744

9. Adam MK, Weinstock BM, Kasi SK. Patient Comfort with Yellow (577 nm) vs. Green (532 nm) Laser Panretinal Photocoagulation for Proliferative Diabetic Retinopathy. Ophthalmol Retina 2018; 2(2): 91-95.

https://doi.org/10.1016/j.oret.2017.05.012

10. Kozak I, Luttrull JK. Modern retinal laser therapy. Saudi J Ophthalmol 2015; 29(2): 137-146.

https://doi.org/10.1016/j.sjopt.2014.09.001

11. Gao Z, Zhang Y, Gao X. Clinical analysis and predictive factors associated with improved visual acuity of infectious endophthalmitis. BMC Ophthalmol 2020; 20(1): 256.

https://doi.org/10.1186/s12886-020-01517-7

12. Evans JR, Michelessi M, Virgili G. Laser photocoagulation for proliferative diabetic retinopathy. Cochrane Database Syst Rev 2014; 2014(11): CD011234.

https://doi.org/10.1002/14651858.CD011234.pub2

13. Feist JE, Drummond SC, Fuerst JS, Crosson JN, Feist RM Sr. Peripheral PRP in the Operating Room vs Standard Clinic PRP for the Initial Treatment of PDR. J Vitreoretin Dis 2024; 8(4): 388-393. https://doi.org/10.1177/24741264241245628

14. Tashjian RZ, Hung M, Keener JD. Determining the minimal clinically important difference for the American Shoulder and Elbow Surgeons score, Simple Shoulder Test, and visual analog scale (VAS) measuring pain after shoulder arthroplasty. J Shoulder Elbow Surg 2017; 26(1): 144-148.

https://doi.org/10.1016/j.jse.2016.06.007

15. Wang S, Hua R, Zhao Y, Liu L. Laser Treatment for Diabetic Retinopathy: History, Mechanism, and Novel Technologies. J Clin Med 2024; 13(18): 5439.

https://doi.org/10.3390/jcm13185439

16. Wu WC, Hsu KH, Chen TL, Hwang YS, Lin KK, Li LM, et al. Interventions for relieving pain associated with panretinal photocoagulation: a prospective randomized trial. Eye 2006; 20(6): 712-719.

https://doi.org/10.1038/sj.eye.6701989

17. Tesha PE, Giavedoni LR, Berger AR, Altomare F, Chow DR, Navajas EV, et al. Subconjunctival lidocaine before laser treatment: a randomized trial. Ophthalmology 2010; 117(9): 1810-1814.

https://doi.org/10.1016/j.ophtha.2010.01.036

18. Mirshahi A, Lashay A, Roozbahani M. Pain score of patients undergoing single spot, short pulse laser versus conventional laser for diabetic retinopathy. Graefes Arch Clin Exp Ophthalmol 2013; 251(4): 1103-1107.

https:/doi.org/10.1007/s00417-012-2167-5